Premium
Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ?
Author(s) -
Giuliano Katherine,
Nagarajan Neeraja,
Canner Joseph,
Najafian Alireza,
Wolfgang Christopher,
Schneider Eric,
Meyer Christian,
Len Anne Marie,
Johnston Fabian M.,
Ahuja Nita
Publication year - 2017
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.24514
Subject(s) - gist , medicine , small intestine , gastroenterology , large intestine , stomach , gastrointestinal tract , stromal cell
Background and Objectives Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Previous literature has suggested that small intestine GISTs are more aggressive than gastric GISTs. Our primary objective was to compare the outcomes of gastric and small intestine GISTs in the decade after approval of imatinib for treatment. Methods The SEER database was queried for cases of gastric and small intestine GIST between the years 2002 and 2012, using the ICD‐O‐3 histology code 8936. Survival analysis was performed using generalized gamma models for time to cause‐specific mortality (CSM). Results CSM was 14.0% for the 3,759 gastric GIST patients and 14.3% for the 1,848 small intestine GIST patients. Five‐year survival was 82.2% and 83.3% for gastric and small intestine patients, respectively. The number of diagnosed cases of GIST increased over the course of this study, especially for tumors <5 cm in size and in patients over age 50 years. Conclusions In this large nation‐wide study, we found that patients with gastric and small intestine GISTs had similar outcomes, in contrast to previous reports. The diagnosis of GIST has significantly increased in the last decade, which may reflect the increased recognition of this entity and frequent use of imaging. J. Surg. Oncol. 2017;115:351–357 . © 2016 Wiley Periodicals, Inc.